INT174100

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.31
First Reported 2003
Last Reported 2010
Negated 5
Speculated 0
Reported most in Body
Documents 14
Total Number 14
Disease Relevance 12.42
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (YWHAE) mitochondrion (YWHAE) protein targeting (YWHAE)
enzyme binding (YWHAE) cytoplasm (YWHAE)
Anatomy Link Frequency
liver 1
YWHAE (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 6 81.76 Quite High
Neuropathic pain 6 50.00 Quite Low
Pain 62 38.88 Quite Low
Pain management 4 32.88 Quite Low
abdominal pain 5 32.72 Quite Low
Bioavailability 27 5.00 Very Low Very Low Very Low
Potency 16 5.00 Very Low Very Low Very Low
adenocard 4 5.00 Very Low Very Low Very Low
anticonvulsant 4 5.00 Very Low Very Low Very Low
peripheral neuropathy 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Myelodysplastic Syndromes 400 100.00 Very High Very High Very High
Thalassemia 60 100.00 Very High Very High Very High
Sickle Cell Anemia 24 100.00 Very High Very High Very High
Blister 8 100.00 Very High Very High Very High
Myeloid Leukemia 196 99.90 Very High Very High Very High
Chronic Myeloid Leukemia 20 99.90 Very High Very High Very High
Chromosome Aberrations 11 98.68 Very High Very High Very High
Sleep Disorders 13 98.24 Very High Very High Very High
Fatigue 41 97.72 Very High Very High Very High
Generaliased Trisomy 1 97.60 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Patient perspectives in MDS and azacitidine
Gene_expression (perspectives) of MDS associated with myelodysplastic syndromes
1) Confidence 0.31 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2939768 Disease Relevance 2.00 Pain Relevance 0.08
Research into the effectiveness of MDS is urgently required.
Gene_expression (effectiveness) of MDS associated with myelodysplastic syndromes
2) Confidence 0.16 Published 2009 Journal Quality & Safety in Health Care Section Body Doc Link PMC2762085 Disease Relevance 0.27 Pain Relevance 0
For each drug, it was noted if it was contained in an MDS or not, and if so, whether it was in a cassette MDS or blister-pack MDS.
Neg (not) Gene_expression (contained) of MDS associated with blister and myelodysplastic syndromes
3) Confidence 0.16 Published 2009 Journal Quality & Safety in Health Care Section Body Doc Link PMC2762085 Disease Relevance 0.39 Pain Relevance 0
For each drug, it was noted if it was contained in an MDS or not, and if so, whether it was in a cassette MDS or blister-pack MDS.
Neg (not) Gene_expression (contained) of MDS associated with blister and myelodysplastic syndromes
4) Confidence 0.16 Published 2009 Journal Quality & Safety in Health Care Section Body Doc Link PMC2762085 Disease Relevance 0.40 Pain Relevance 0
For each drug, it was noted if it was contained in an MDS or not, and if so, whether it was in a cassette MDS or blister-pack MDS.
Neg (not) Gene_expression (contained) of MDS associated with blister and myelodysplastic syndromes
5) Confidence 0.16 Published 2009 Journal Quality & Safety in Health Care Section Body Doc Link PMC2762085 Disease Relevance 0.40 Pain Relevance 0
QIOs found that it was imperative to have an MDS expert (e.g., an MDS consultant or the state RAI coordinator) participate in the training sessions to clarify questions about appropriate coding for some of the MDS items, as there is tremendous variation in how nursing home staff code the MDS for the same MDS items.


Gene_expression (expert) of MDS associated with myelodysplastic syndromes
6) Confidence 0.15 Published 2003 Journal BMC Geriatr Section Body Doc Link PMC166131 Disease Relevance 0.62 Pain Relevance 0
MCE can be interpreted as the ‘minimum curvilinear’ extension of MDS.
Gene_expression (extension) of MDS associated with myelodysplastic syndromes
7) Confidence 0.12 Published 2010 Journal Bioinformatics Section Body Doc Link PMC2935424 Disease Relevance 0.47 Pain Relevance 0
Although CR rates in AML and MDS range between 10-20%, the major advantages of epigenetic therapy is hematologic improvement, transfusion independency, and delayed transformation into AML, which results into prolonged survival, especially in MDS patients.
Gene_expression (range) of MDS associated with myeloid leukemia and myelodysplastic syndromes
8) Confidence 0.06 Published 2008 Journal Current Medicinal Chemistry Section Body Doc Link PMC2764862 Disease Relevance 0.78 Pain Relevance 0
In these patients, independent predictors for achieving IWG CR were chronic myelomonocytic leukaemia (CMML) vs MDS, shorter duration of MDS, and no prior MDS therapy, especially when combined.
Neg (no) Gene_expression (therapy) of MDS associated with myelodysplastic syndromes and chronic myeloid leukemia
9) Confidence 0.06 Published 2008 Journal Current Medicinal Chemistry Section Body Doc Link PMC2764862 Disease Relevance 1.02 Pain Relevance 0
Accordingly, it has been shown that DNMT1 and DNMT3A are overexpressed in MDS and AML samples, when compared to controls [42].
Gene_expression (overexpressed) of MDS associated with myeloid leukemia and myelodysplastic syndromes
10) Confidence 0.06 Published 2008 Journal Current Medicinal Chemistry Section Body Doc Link PMC2764862 Disease Relevance 1.12 Pain Relevance 0
In these patients, independent predictors for achieving IWG CR were chronic myelomonocytic leukaemia (CMML) vs MDS, shorter duration of MDS, and no prior MDS therapy, especially when combined.
Neg (no) Gene_expression (therapy) of MDS associated with myelodysplastic syndromes and chronic myeloid leukemia
11) Confidence 0.06 Published 2008 Journal Current Medicinal Chemistry Section Body Doc Link PMC2764862 Disease Relevance 1.03 Pain Relevance 0
-thalassemia, SCD and MDS.78–81 In one study, 97% of patients with ?
Gene_expression (thalassemia) of MDS associated with sickle cell anemia, thalassemia and myelodysplastic syndromes
12) Confidence 0.05 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2773754 Disease Relevance 0.62 Pain Relevance 0
-thalassemia population, deferasirox has dose-dependent efficacy in patients with MDS.22 The largest cohort of MDS patients (n = 341) ever assessed with iron chelation therapy were enrolled in the EPIC study; with appropriate dose adjustments, significant reductions in serum ferritin were noted after 1 year of deferasirox treatment (Table 2).26,31 Another large study in 176 heavily iron-overloaded MDS patients also showed decreases in serum ferritin.46 Preliminary data suggest that in addition to decreases in serum ferritin, improvements in hematological parameters can occur with deferasirox treatment in patients with MDS.49 Serum ferritin decreases during deferasirox treatment in patients with MDS have been shown to be associated with significant improvements in alanine aminotransferase (ALT), which is an indicator of hepatocellular injury.47,50 This is of importance given that liver dysfunction is a common complication in MDS;51,52 prospective studies are warranted to further investigate this observation.
Gene_expression (decreases) of MDS in liver associated with injury, thalassemia, hepatotoxicity and myelodysplastic syndromes
13) Confidence 0.05 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2773754 Disease Relevance 1.17 Pain Relevance 0
He was initially diagnosed with MDS five years ago, having a single cytogenetic abnormality of trisomy 19.
Gene_expression (diagnosed) of MDS associated with chromosome aberrations, myelodysplastic syndromes and generaliased trisomy
14) Confidence 0.03 Published 2008 Journal Ann Clin Microbiol Antimicrob Section Body Doc Link PMC2276236 Disease Relevance 2.10 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox